3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
57
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
tremelimumab
4
Ipilimumab
4
lenvatinib
3
durvalumab
3
Nivolumab
3
pembrolizumab
2
balstilimab
2
Pemetrexed
2
Carboplatin
2
Bevacizumab
2
spartalizumab
1
relatlimab
1
poly ICLC
1
osimertinib
1
cemiplimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Platinum
1
Peptides
1
Paclitaxel
1
Opdualag
1
Docetaxel
1
Capecitabine
1
Blood Specimen Collection
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
trastuzumab deruxtecan
×
1 year
×
Clear all
No trials found.